Vγ9Vδ2 TCR Lentivirus
Vγ9Vδ2 TCR Lentivirus are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These viruses transduce a TCR (T Cell Receptor) which belongs to the Vγ9Vδ2 subtype of γδ TCRs. The TCR γ chain and δ chain are linked by P2A. The lentiviruses also transduce a puromycin selection marker (Figure 1).
Figure 1. (A) Schematic of the lenti-vector used to generate the Vγ9Vδ2 TCR Lentivirus and (B) diagram of the construct, showing the components of the Vγ9Vδ2 TCR.
TRGV and TRGC correspond to the TCR γ chain variable and constant regions, respectively, whereas TRDV and TRDC correspond to the TCR δ chain variable and constant regions.
Name | Ordering Information |
Thaw Medium 2 | BPS Bioscience #60184 |
Growth Medium 2B | BPS Bioscience #79530 |
Growth Medium 2F | BPS Bioscience #79669 |
TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line | BPS Bioscience #78556 |
Anti-CD3 Agonist Antibody | BPS Bioscience #71274 |
TCR Vδ2 Antibody, anti-human, PE, REAfinity™ | Miltenyi Biotech #130-111-127 |
TCR V delta 2 Monoclonal Antibody (15D) | Life Technologies #TCR1732 |
TCR V delta 1 Monoclonal Antibody (TS8.2) | Life Technologies #TCR1730 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Lenti-Fuse Polybrene Viral Transduction Enhancer | BPS Bioscience #78939 |
The lentiviruses were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations by special request, for an additional fee.
γδ TCRs (T cell receptors), αβ TCRs, and antibodies, result from gene rearrangements and offer the immune system the possibility to recognize several different types of antigens. γδ TCRs recognize antigens in a similar way to antibodies, being able to recognize full protein antigens and being independent on antigen binding to the MHC (major histocompatibility complex). Examples of such antigens include pyrophosphomonoesters from Mycobacterium tuberculosis and E. Coli, or glycoprotein I from Herpes simplex. γδ TCRs are cell type specific, with Vγ9Vδ2 being present in T cells and corresponding to about 5% of the T cell population in blood. Vγ9Vδ2 T cells are involved mostly in immune responses to pathogens and long-term modulation of inflammation, and can recognize non-peptide phospho-antigens, alkylamines and synthetic aminobisphosphonates. Vγ9Vδ2 T cells are being studied for the treatment of solid tumors and hematological disorders and are becoming a highly promising cancer therapy. Further studies on how best to utilize Vγ9Vδ2 T cells, and methods to enhance their presence, will open new therapeutic avenues for cancer and infections.
Allison T. and Garboczi D., 2002 Molecular Immunology 38 (14): 1051-1061.
Sawaisorn P., et al., 2024 Scientific Reports 14: 1291.